Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522495 · ClinicalTrials.gov registry record · NA
Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging
A NA study, sponsored by Georgetown University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT01522495 is a NA study that has completed, run by Georgetown University. The registered enrollment target is 31 participants.
The verdict
NCT01522495, a NA study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell pathway would indicate where the line of demarcation should be drawn. The information generated would better predict clinical outcome using SPY Imaging. Cellular studies are needed to successfully confirm a clear line of demarcation to eliminate surgeon subjectivity.
Interventions
- DEVICE SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
- DEVICE SPY Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522495
The ClinicalTrials.gov registry entry for NCT01522495 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) is the first listed.
NCT01522495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522495 about?
NCT01522495 is a clinical study titled "Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging". Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell path...
What is the current status of trial NCT01522495?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2013-04. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01522495?
The interventions under investigation include: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) (DEVICE), SPY Imaging (DEVICE).
Who is sponsoring clinical trial NCT01522495?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.